Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

NEXT STORY
Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients
PREV STORY
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

“New To The Street” TV Announces Two Televised Broadcastings, One on Bloomberg Television, Today, Saturday, April 24, 2021 @ 6 Pm EDT, and a Second Broadcasting on Newsmax TV, Tomorrow, Sunday, April 25, 2021- Hour Slot 10-11am EDT

author_avatar
NASDAQ Market News

INNATE PHARMA : Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas

Preliminary data from the dose-escalation part of an ongoing Phase I trial in elderly ...

author_avatar
NASDAQ Market News

Exagen enters second-year agreement with GSK to drive greater awareness about challenges facing lupus diagnosis and management

author_avatar
NASDAQ Market News